Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been diagnosed with metastatic triple-negative breast cancer (a type of breast cancer confirmed by tissue testing that has spread to other parts of the body)
- People who have at least one tumour site that is suitable for cryoablation (a procedure that uses extreme cold to destroy tumour tissue), measuring at least 1.5 cm, as determined by a specialist radiologist — eligible sites can include soft tissue, liver, lung, or bone
- People who are physically well enough to undergo cryoablation, as assessed through standard clinical practice
- People for whom pembrolizumab (an immunotherapy drug, 200 mg every 3 weeks) is already planned as part of their standard cancer treatment, as a first, second, or third line of therapy — this must be determined by the patient's own cancer specialist
- People whose cancer specialist has determined they are suitable for a PD-1 inhibitor (a type of immunotherapy) as part of their treatment plan
- People whose treatment plan may also include certain other chemotherapy medicines, such as paclitaxel, carboplatin, gemcitabine, or others from a specified list — the timing of these medicines alongside pembrolizumab and cryoablation is flexible
- Women aged 11–50 who have the potential to become pregnant will need to have a pregnancy test within 2 weeks before cryoablation (this requirement does not apply to those who have had certain surgeries, are post-menopausal, or have been surgically sterilised, with supporting documentation)
- Women of childbearing age are expected to use effective contraception during pembrolizumab treatment and for at least 4 months after the last dose, as monitored by their cancer specialist
Who may not be able to join:
- People whose cancer specialist has determined they are not suitable for a PD-1 inhibitor
- People who do not have any tumour sites that a specialist radiologist considers suitable for cryoablation
- People for whom pembrolizumab is not already planned as part of their standard care
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yolanda Bryce, MD, Memorial Sloan Kettering Cancer Center
Phone: 212-639-6530
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in CD4-PD1 from baseline to post-cryoablation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.